// App-Quantinova.ai

671 : Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

Researchers

Presenter

  • Deborah A. Thomas

Principal Investigators

  • Jeffrey L. Jorgensen

  • Hagop M. Kantarjian

  • Partow Kebriaei

  • Farhad Ravandi

  • Monica Kwari

  • Stefan Faderl

  • Jorge E. Cortes

  • Elias J. Jabbour

  • Sergernne York

  • Rebecca Garris

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Acute lymphoblastic leukemia

  • Gastric antral vascular ectasia

Biomarkers

  • Breakpoint Cluster Region

  • C reactive protein

Drug/Treatment

  • Inotuzumab ozogamicin

  • LL-33288

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved